A Multi-Objective Approach for Drug Repurposing in Preeclampsia

• Published in: Molecules (Basel, Switzerland) Switzerland), 2021-02, Vol.26 (4), p.777
• Main Authors: Tejera, Eduardo, Pérez-Castillo, Yunierkis, Chamorro, Andrea, Cabrera-Andrade, Alejandro, Sanchez, Maria Eugenia
• Format: Article
• Language: English
• Subjects: 17β-Estradiol; Angiotensin; Antibiotics; Antihypertensive Agents - chemistry; Antihypertensive Agents - therapeutic use; Antihypertensives; Antiparasitic agents; Cancer; Clinical trials; Databases, Pharmaceutical; Diabetes; Disease; Drug Repositioning; Drugs; drugs repurposing; ErbB-2 protein; Female; Fetuses; Gene expression; Genetic algorithms; Humans; Hypertension; machine learning; Metabolism; Model accuracy; Models, Cardiovascular; Molecular modelling; multi-objective models; Multiple objective analysis; Optimization; Pathogenesis; Placenta; Pre-eclampsia; Pre-Eclampsia - drug therapy; Preeclampsia; Pregnancy; Proteins; Sex hormones; Simvastatin; Transcription factors; Vitamin D; Vitamins
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules26040777

Preeclampsia is a hypertensive disorder that occurs during pregnancy. It is a complex disease with unknown pathogenesis and the leading cause of fetal and maternal mortality during pregnancy. Using all drugs currently under clinical trial for preeclampsia, we extracted all their possible targets from the DrugBank and ChEMBL databases and labeled them as "targets". The proteins labeled as "off-targets" were extracted in the same way but while taking all antihypertensive drugs which are inhibitors of ACE and/or angiotensin receptor antagonist as query molecules. Classification models were obtained for each of the 55 total proteins (45 targets and 10 off-targets) using the TPOT pipeline optimization tool. The average accuracy of the models in predicting the external dataset for targets and off-targets was 0.830 and 0.850, respectively. The combinations of models maximizing their virtual screening performance were explored by combining the desirability function and genetic algorithms. The virtual screening performance metrics for the best model were: the Boltzmann-Enhanced Discrimination of ROC (BEDROC) = 0.258, the Enrichment Factor (EF) = 31.55 and the Area Under the Accumulation Curve (AUAC) = 0.831. The most relevant targets for preeclampsia were: AR, VDR, SLC6A2, NOS3 and CHRM4, while ABCG2, ERBB2, CES1 and REN led to the most relevant off-targets. A virtual screening of the DrugBank database identified estradiol, estriol, vitamins E and D, lynestrenol, mifrepristone, simvastatin, ambroxol, and some antibiotics and antiparasitics as drugs with potential application in the treatment of preeclampsia.